Susanne Kossatz studied Biology at the Friedrich Schiller University Jena from where she also obtained her PhD in the field of Molecular Imaging under the supervision of Prof. Hilger in 2013. She conducted her postdoctoral studies at Memorial Sloan Kettering Cancer Center in New York between 2014 and 2019, first as research fellow and later as research associate. There, her research in the Thomas Reiner lab focused on preclinical evaluation and clinical translation of fluorescently and radioactively labeled PARP inhibitors. In April 2019, she was awarded a Rudolf Mößbauer Tenure Track Assistant Professorship in the Department of Nuclear medicine, where she heads the research group “Imaging and Biomarkers in Oncology”.
2019 Named one of “30 under 35” early career professionals “to watch” in 2019 by the Society of Nuclear Medicine and Molecular Imaging (SNMMI)
2018 K99/R00 “Pathway to Independence” Award
2015 Research Fellowship for a Postdoctoral Fellow from the Center of Molecular Imaging and Nanotechnology (CMINT) at Memorial Sloan Kettering Cancer Center
2015-2019 Chief Laboratory Research Fellow in the Dept. of Radiology at Memorial Sloan Kettering Cancer Center
2015 Young Investigator Award from the Center for Molecular Imaging Innovation and Translation (CMIIT) at the Society of Nuclear Medicine and Nuclear Imaging (SNMMI) annual meeting
2014 Research Fellowship from the German Research Foundation
2011 Young Investigator Award, 92nd German Radiology Conference
My research interests involve the development and clinical translation of molecular imaging tools for improved tumor detection, intraoperative delineation, treatment and monitoring with the long-term goal to improve outcome and survival for patients. My research strategy involves investigating fluorescent and nuclear imaging probes for their suitability in molecular imaging applications and translation. This includes preclinical (in vitro and in vivo) studies, in-depth work with human biospecimens as well as implementation of early phase clinical studies. Among many promising biomarkers, fluorescent- and radiolabeled PARP inhibitors have been a specific research focus for applications ranging from brain tumor imaging and therapy to early detection and intraoperative guidance of oral and esophageal cancer.
Vargas SH, Kossatz S, Voss J, Ghosh SC, Cao HST, Simien J, Reiner T, Dhingra S, Fisher WE, Azhdarinia A, 2019. Specific targeting of somatostatin receptor subtype-2 for fluorescence-guided surgery. Clinical Cancer Research, 2019, pp.clincanres-3312 [Epub ahead of print] PMID: 31015345
Kossatz S*, Carney B, Farley C, Drain CM, Weber WA, Reiner T. Direct imaging of drug distribution and target engagement of the PARP inhibitor rucaparib. Journal of Nuclear Medicine, 2018, 59 (8), 1316-1320. *corresponding author. PMID: 29572258.
Jannetti, SA, Carlucci G, Carney B, Kossatz S, Shenker L, Salinas B, Brand C, Sadique A, Donabedian PL, Cunanan KM, Gonen M, Ponomarev V, Zeglis BM, Souweidane MM, Lewis JS, Weber WA, Humm JL, Reiner T. PARP1-targeted radiotherapy in mouse models of glioblastoma. Journal of Nuclear Medicine, 2018, 59 (8), 1225-1233. PMID: 29572254.
Carney B, Kossatz S, Lok BH, Schneeberger V, Gangangari KK, Pillarsetty N, Weber WA, Rudin CM, Poirier JT, Reiner T. Target Engagement Imaging of PARP Inhibitors in Small Cell Lung Cancer. Nature Communications, 2018, Jan 12;9(1):176. PMID: 29330466.
Tang J, Salloum D, Carney B, Brand C, Kossatz S, Sadique A, Weber WA, Wendel HG, Reiner T. A Targeted PET Imaging Strategy to Differentiate Malignant from Inflamed Lymph Nodes in Diffuse Large B-Cell Lymphoma. Proceedings of the National Academy of Sciences, 2017, 201705013. PMID: 28827325.
Kossatz S, Carney B, Schweitzer ME, Carlucci G, Miloushev V, Maachani UB, Rajappa P, Keshari KR, Pisapia D, Weber WA, Souweidane MM, Reiner T. Biomarker based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models. Cancer Research, 2017, 77.8: 2112-2123. PMID: 28108511.
Kossatz S, Brand C, Gutiontov S, Liu JTC, Lee N, Gonen M, Weber WA, Reiner T. Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent. Nature Scientific Reports, 2016, 21371. PMID: 26900125.
Kossatz S, Weber AW, Reiner T. Optical Imaging of PARP1 in response to radiation in Oral Squamous Cell Carcinoma. PloS one, 2016, 11.1: e0147752. PMID: 26808835.
Kossatz S, Grandke J, Couleaud P, Latorre A, Aires A, Crosbie-Staunton K, Ludwig R, Daehring H, Ettelt V, Lazaro-Carrillo A, Calero M, Sader M, Courty J, Volkov Y, Prina-Mello A, Villanueva A, Somoza A, Cortajareno AL, Miranda R, Hilger I. Efficient treatment of breast cancer xenografts with multifunctionalized iron oxide nanoparticles combining magnetic hyperthermia and anti-cancer drug delivery. Breast Cancer Research, 2015, 17(1), 66. PMID: 25968050.
Kossatz S*, Ludwig R*, Dähring H, Ettelt V, Rimkus G, Marciello M, Salas G, Patel V, Teran FJ, Hilger I. High therapeutic efficiency of magnetic hyperthermia in xenograft models achieved with moderate temperature dosages in the tumor area. Pharmaceutical Research, 2014, 31(12), 3274–88. *contributed equally PMID: 24890197.
Kossatz S, Béhé M, Mansi R, Czerney P, Kaiser WA, Hilger I. Multifactorial diagnostic imaging of CCK2R expressing tumors. Biomaterials, 2013, 34(21): 5172–5180. PMID: 23591397.
A full list of publications can be found here: https://www.ncbi.nlm.nih.gov/pubmed/?term=susanne+kossatz